OBJECTIVE: This study tests the hypothesis that methylprednisolone may influence eNOS activity in renal arterial and venous vascular beds and impede subclinical renal injury. SUMMARY BACKGROUND DATA: Acute renal failure is a major complication of cardiovascular surgery. Renal damage arises in part from excessive vasoconstriction mediated by an imbalance of vasoconstrictive ET-1 and vasodilatory NO produced by eNOS. While methylprednisolone may reduce subclinical renal injury as measured by urinary N-acetyl-beta-D-glucosaminidase (beta-NAG), its effects upon eNOS activity in renal arterial and venous vascular beds, reflected by urinary nitrate levels, is unclear. METHODS: A porcine model of normotensive, euvolemic infrarenal aortic ischaemia-reperfusion was used. Forty-two pigs underwent a 60-minute laparotomy followed by 150 minutes of infrarenal ischemia and 180 minutes of reperfusion. Animals were randomized to receive methylprednisolone 30 mg/kg or placebo after induction of general anesthesia. Urinary beta-NAG levels were assessed as an index of subclinical renal injury, whereas urinary nitrate was assessed as an indicator of eNOS activity in renal arterial and venous vascular beds. RESULTS: Methylprednisolone treatment did not influence mean arterial, central venous, or pulmonary artery wedge pressures but suppressed plasma IL-6 levels. After the ischemia-induced rise from preanaesthetic baseline levels, urinary beta-NAG levels declined to significantly lower values in the MP group, indicative of MP renal protection (P < 0.05). Conversely, urinary nitrate levels indicative of vascular e-NOS activity remained significantly and persistently higher in MP-treated animals (P < 0.05). CONCLUSION: This study, in a porcine model of renal ischaemia-reperfusion injury, shows the benefits of methylprednisolone pretreatment in enhancing urinary nitrate levels indicative of vascular eNOS activity and the reduction of urinary beta-NAG levels, which represent subclinical renal injury.
OBJECTIVE: This study tests the hypothesis that methylprednisolone may influence eNOS activity in renal arterial and venous vascular beds and impede subclinical renal injury. SUMMARY BACKGROUND DATA: Acute renal failure is a major complication of cardiovascular surgery. Renal damage arises in part from excessive vasoconstriction mediated by an imbalance of vasoconstrictive ET-1 and vasodilatory NO produced by eNOS. While methylprednisolone may reduce subclinical renal injury as measured by urinary N-acetyl-beta-D-glucosaminidase (beta-NAG), its effects upon eNOS activity in renal arterial and venous vascular beds, reflected by urinary nitrate levels, is unclear. METHODS: A porcine model of normotensive, euvolemic infrarenal aortic ischaemia-reperfusion was used. Forty-two pigs underwent a 60-minute laparotomy followed by 150 minutes of infrarenal ischemia and 180 minutes of reperfusion. Animals were randomized to receive methylprednisolone 30 mg/kg or placebo after induction of general anesthesia. Urinary beta-NAG levels were assessed as an index of subclinical renal injury, whereas urinary nitrate was assessed as an indicator of eNOS activity in renal arterial and venous vascular beds. RESULTS:Methylprednisolone treatment did not influence mean arterial, central venous, or pulmonary artery wedge pressures but suppressed plasma IL-6 levels. After the ischemia-induced rise from preanaesthetic baseline levels, urinary beta-NAG levels declined to significantly lower values in the MP group, indicative of MP renal protection (P < 0.05). Conversely, urinary nitrate levels indicative of vascular e-NOS activity remained significantly and persistently higher in MP-treated animals (P < 0.05). CONCLUSION: This study, in a porcine model of renal ischaemia-reperfusion injury, shows the benefits of methylprednisolone pretreatment in enhancing urinary nitrate levels indicative of vascular eNOS activity and the reduction of urinary beta-NAG levels, which represent subclinical renal injury.
Authors: Ali Hafezi-Moghadam; Tommaso Simoncini; Zequan Yang; Florian P Limbourg; Jean-Christophe Plumier; Michael C Rebsamen; Chung-Ming Hsieh; Dao-Shan Chui; Kennard L Thomas; Alyson J Prorock; Victor E Laubach; Michael A Moskowitz; Brent A French; Klaus Ley; James K Liao Journal: Nat Med Date: 2002-05 Impact factor: 53.440
Authors: N J Jansen; W van Oeveren; M van Vliet; C P Stoutenbeek; L Eysman; C R Wildevuur Journal: Eur J Cardiothorac Surg Date: 1991 Impact factor: 4.191
Authors: S M Gormley; W T McBride; M A Armstrong; I S Young; E McClean; S W MacGowan; G Campalani; T J McMurray Journal: Anesthesiology Date: 2000-11 Impact factor: 7.892
Authors: William T McBride; Stephen Allen; Sheena M C Gormley; Ian S Young; Elizabeth McClean; Simon W MacGowan; Peter Elliott; Terence J McMurray; Marilyn A Armstrong Journal: Cytokine Date: 2004 Jul 21-Aug 7 Impact factor: 3.861
Authors: Sanjeev Kumar; David A Allen; Julius E Kieswich; Nimesh S A Patel; Steven Harwood; Emanuela Mazzon; Salvatore Cuzzocrea; Martin J Raftery; Christoph Thiemermann; Muhammad M Yaqoob Journal: J Am Soc Nephrol Date: 2009-09-24 Impact factor: 10.121
Authors: Mary Jo Kurth; William T McBride; Gavin McLean; Joanne Watt; Anna Domanska; John V Lamont; Daniel Maguire; Peter Fitzgerald; Mark W Ruddock Journal: Sci Rep Date: 2020-11-17 Impact factor: 4.379